Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-14T09:19:40.455Z Has data issue: false hasContentIssue false

A Double-Blind, Randomised, Placebo-Controlled Trial of Cytisine for Smoking Cessation in Medium-Dependent Workers

Published online by Cambridge University Press:  21 February 2012

Denis Vinnikov*
Public Association ‘Lung Health’, Bishkek, Kyrgyzstan; Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan.
Nurlan Brimkulov
Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan.
Aichurek Burjubaeva
Public Association ‘Lung Health’, Bishkek, Kyrgyzstan.
*Address for correspondence: Denis Vinnikov, Public Association ‘Lung Health’, Togolok Moldo street, 1, Bishkek, Kyrgyzstan.


Among many studies on cytisine only a few have been controlled trials, and the aim of this study was to assess the efficacy of cytisine in a randomized controlled double-blind trial compared to placebo in medium-dependent smoking men working in mining industry. Materials and methods: 171 middle-aged smokers were randomised to either cytisine (25-days regimen) or placebo; both groups received individual counseling with brochure. Self-reported continuous abstinence was assessed at 8 and 26 weeks. Results: At the end of week 8 there were no differences in number of abstinent subjects, but at 26 weeks 10.6% of subjects were abstinent in cytisine group compared to 1.2% in placebo (p = .01). In both groups, we did not find any weight increase, but quality of life improved in both groups, and physical and social functioning improved in cytisine group. Conclusions: Cytisine may be an effective medication to help smokers quit even for those working in difficult working conditions with high relapse rate.

Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)